F Fresh Tracks Therapeutics, Inc.: insider trades · United States · SEC (Form 4) Discover the full directors' dealings record of Fresh Tracks Therapeutics, Inc., a publicly traded company based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was filed on 11 June 2024 (Acquisition). Among the most active insiders: Exploration Capital, LLC. The full history is openly available.
€709,911
19 ops.
Buy Volume
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Last declaration on 11 June 2024
All Executives24 Thresholds0 Prospectus0 Other0
Declarations 24 total
319,315 shares @ US$0.94 39.1% of flow Common Stock SEC:0001213900-24-051866:0
Ideal exit: 4 Mar 2025 (T+270) 80 shares @ US$0.87 0.0% of flow Common Stock SEC:0001213900-24-048558:0
Ideal exit: 23 Feb 2025 (T+270) 6,879 shares @ US$0.91 0.8% of flow Common Stock SEC:0001213900-24-046344:0
Ideal exit: 15 Feb 2025 (T+270) 73,768 shares @ US$0.92 8.9% of flow Common Stock SEC:0001213900-24-045315:0
Ideal exit: 10 Feb 2025 (T+270) 320 shares @ US$0.89 0.0% of flow Common Stock SEC:0001213900-24-040869:0
Ideal exit: 31 Jan 2025 (T+270) 162,351 shares @ US$0.92 19.8% of flow Common Stock SEC:0001213900-24-039764:0
Ideal exit: 26 Jan 2025 (T+270) 4,277 shares @ US$0.91 0.5% of flow Common Stock SEC:0001213900-24-035431:0
Ideal exit: 14 Jan 2025 (T+270) 2,188 shares @ US$0.88 0.3% of flow Common Stock SEC:0001213900-24-032240:0
Ideal exit: 4 Jan 2025 (T+270) 12,928 shares @ US$0.91 1.5% of flow Common Stock SEC:0001213900-24-030877:0
Ideal exit: 29 Dec 2024 (T+270) 51,634 shares @ US$0.90 6.1% of flow Common Stock SEC:0001213900-24-028916:0
Ideal exit: 22 Dec 2024 (T+270) 10 shares @ US$0.90 0.0% of flow Common Stock SEC:0001213900-24-024839:0
Ideal exit: 14 Dec 2024 (T+270) 5,703 shares @ US$0.91 0.7% of flow Common Stock SEC:0001213900-24-022246:0
Ideal exit: 6 Dec 2024 (T+270) 20,109 shares @ US$0.90 2.4% of flow Common Stock SEC:0001213900-24-018112:0
Ideal exit: 22 Nov 2024 (T+270) 49,951 shares @ US$0.88 5.8% of flow Common Stock SEC:0001213900-24-016223:0
Ideal exit: 16 Nov 2024 (T+270) 10,958 shares @ US$0.98 1.4% of flow Common Stock SEC:0001213900-24-004190:0
Ideal exit: 8 Oct 2024 (T+270) 38,017 shares @ US$0.98 4.8% of flow Common Stock SEC:0001213900-24-003009:0
Ideal exit: 5 Oct 2024 (T+270) 23,877 shares @ US$0.89 2.8% of flow Common Stock SEC:0001213900-24-001658:0
Ideal exit: 29 Sept 2024 (T+270) 47,000 shares @ US$0.84 5.1% of flow Common Stock SEC:0001213900-23-097429:0
Ideal exit: 15 Sept 2024 (T+270) ▼ VP of Finance & CAO · Executives · 8 Dec 2023
74 shares @ US$0.91 100.0% of flow Common Stock SEC:0001628280-23-041229:0
◇ Former Chief R&D Officer & COO · Executives · 1 Sept 2023
35,000 shares Common Stock SEC:0001628280-23-041230:0
7,579 shares @ US$0.85 100.0% of flow Common Stock SEC:0001213900-23-093858:0
Ideal exit: 30 Aug 2024 (T+270) ▼ VP of Finance & CAO · Executives · 4 Dec 2023
36.44 shares @ US$0.8501 100.0% of flow Common Stock SEC:0001628280-23-040639:0
◇ President and CEO · Executives · 2 Oct 2023
55,000 shares Common Stock SEC:0001628280-23-033916:0
◇ Gen Counsel, CCO, & Secretary · Executives · 2 Oct 2023
20,000 shares Common Stock SEC:0001628280-23-033914:0